Evidence map›Paper›PMID 28427232›Full record

ArticleOncotarget2017

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.

Wilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, Irene Jimenez, Laetitia Maillot, David Gentien, Benoît Albaud, Walid Chemlali, Christine Galant, Frederique Larousserie and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Wilfrid RicherParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Julien Masliah-PlanchonParis-Sciences-Lettres, Institut Curie Hospital, Laboratory of Somatic Genetics, 75248 Paris Cedex 5, France.
Nathalie ClementParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Irene JimenezParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Laetitia MaillotParis-Sciences-Lettres, Institut Curie Hospital, Laboratory of Somatic Genetics, 75248 Paris Cedex 5, France.
David GentienParis-Sciences-Lettres, Institut Curie Research Center, Department of Translational Research, Genomic Platform, 75248 Paris Cedex 5, France.
Benoît AlbaudParis-Sciences-Lettres, Institut Curie Research Center, Department of Translational Research, Genomic Platform, 75248 Paris Cedex 5, France.
Walid ChemlaliParis-Sciences-Lettres, Institut Curie Hospital, Laboratory of Somatic Genetics, 75248 Paris Cedex 5, France.
Christine GalantUniversity Hospital of Leuven, Department of Pathology, 10-1200 Brussel-Belgium.
Frederique LarousserieCochin University Hospital, Universite Rene Descartes, Sorbonne Paris Cite, Assistance Publique Hôpitaux de Paris, Department of Pathology, 75014 Paris, France.
Pascaline Boudou-RouquetteCochin University Hospital, Assistance Publique Hôpitaux de Paris, Department of Oncology, 75014 Paris, France.
Amaury LerusteParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Celine ChauvinParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Zhi Yan HanParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Jean-Michel CoindreInstitut Bergognie, Department of Pathology, 33000 Bordeaux, France.
Pascale VarletUniversity Sainte-Anne Hospital, 75014 Paris, France.
Paul FreneauxParis-Sciences-Lettres, Institut Curie Hospital, Department of Pathology, 75248 Paris Cedex 5, France.
Dominique Ranchère-VinceCentre Leon Berard, Department of Pathology, 69008, Lyon, France.
Olivier DelattreParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Franck BourdeautParis-Sciences-Lettres, Institut Curie Research Center, INSERMU830 & SiRIC, Laboratory of Translational Research in Pediatric Oncology, 75248 Paris Cedex 5, France.
Institut Curie · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Sainte-Anne · FRCentre Léon Bérard · FRInstitut Bergonié · FRKU Leuven · BESorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extra-cranial rhabdoid tumors (RT) are highly aggressive malignancies of infancy, characterized by undifferentiated histological features and loss of SMARCB1 expression. The diagnosis is all the more challenging that other poorly differentiated cancers lose SMARCB1 expression, such as epithelioid sarcomas (ES), renal medullary carcinomas (RMC) or undifferentiated chordomas (UC). Moreover, late cases occurring in adults are now increasingly reported, raising the question of differential diagnoses and emphasizing nosological issues. To address this issue, we have analyzed the expression profiles of a training set of 32 SMARCB1-deficient tumors (SDT), with ascertained diagnosis of RT (n = 16, all < 5 years of age), ES (n = 8, all > 10 years of age), UC (n = 3) and RMC (n = 5). As compared with other SDT, RT are characterized by an embryonic signature, and up-regulation of key-actors of de novo DNA methylation processes. Using this signature, we then analysed the expression profiling of 37 SDT to infer the appropriate diagnosis. Thirteen adult onset tumors showed strong similarity with pediatric RT, in spite of older age; by exome sequencing, these tumors also showed genomic features indistinguishable from pediatric RT. In contrary, 8 tumors were reclassified within carcinoma, ES or UC categories, while the remaining could not be related to any of those entities. Our results demonstrate that embryonic signature is shared by all RT, whatever the age at diagnosis; they also illustrate that many adult-onset SDT of ambiguous histological diagnosis are clearly different from RT. Finally, our study paves the way for the routine use of expression-based signatures to give accurate diagnosis of SDT.

Indexed as

AdolescentAdultAge of OnsetChildChild, PreschoolDiagnosis, DifferentialDNA MethylationExome SequencingGene Expression ProfilingGene Regulatory NetworksHumansInfantMaleRhabdoid TumorSMARCB1 ProteinYoung AdultSMARCB1 ProteinSMARCB1 protein, humanadultDNMT3BrhabdoidSMARCB1TET1

Identifiers

PMID28427232
PMCPMC5470964
OpenAlexW2594813842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.